Verastem (VSTM)
(Delayed Data from NSDQ)
$9.31 USD
-0.30 (-3.12%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $9.29 -0.02 (-0.21%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Verastem (VSTM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$27.92 | $36.00 | $17.50 | 190.53% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Verastem comes to $27.92. The forecasts range from a low of $17.50 to a high of $36.00. The average price target represents an increase of 190.53% from the last closing price of $9.61.
Analyst Price Targets (6 )
Broker Rating
Verastem currently has an average brokerage recommendation (ABR) of 1.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.14 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, six are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 85.71% and 14.29% of all recommendations. A month ago, Strong Buy made up 85.71%, while Buy represented 14.29%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 5 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.14 | 1.14 | 1.14 | 1.14 | 1.17 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/19/2024 | H.C. Wainwright & Co. | Sean Lee | Strong Buy | Strong Buy |
11/28/2023 | Cantor Fitzgerald & Co | Pete Stavropoulos | Not Available | Strong Buy |
11/21/2023 | BTIG | Justin R Zelin | Not Available | Strong Buy |
11/15/2023 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
9/27/2023 | B. Riley Securities | Kalpit Patel | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.14 |
ABR (Last week) | 1.14 |
# of Recs in ABR | 7 |
Average Target Price | $27.92 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 78 of 252 |
Current Quarter EPS Est: | -1.16 |